Join leading pulmonologists Drs. Njira Lugogo, Simon Couillard, and Mario Castro, as they explore the role of type 2 inflammation in the pathogenesis of mucus plugging in the airways, the burden of excess mucus in patients with moderate-to-severe asthma, and how reducing airway mucus may lead to improved long-term patient outcomes.

Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
Explore the clinical features, complex burden, and underlying mechanisms of PN.
Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.
Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP
In this ADVENT symposium at the 2024 EADV meeting, Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP.
Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.
Professor Joost Meijer discusses the complex etiology and diagnosis of BP
This static infographic covers the clinical presentations, diagnostic challenges, and disease burden of bullous pemphigoid (BP), a chronic relapsing autoimmune skin disease. Review the steps of diagnosis, which include clinical assessment and laboratory work. Explore comorbidities associated with BP and how they impact patient quality of life.

Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.

Dr. Amy Paller discusses how targeting IL-4 and IL-13 can improve burden of AD.